- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in small-molecular therapeutics for COVID-19
Authors
Keywords
-
Journal
Precision Clinical Medicine
Volume 5, Issue 4, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-09-25
DOI
10.1093/pcmedi/pbac024
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis
- (2022) Daniele Focosi et al. ANTIVIRAL RESEARCH
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
- (2022) Jennifer Hammond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Newly synthesized series of oxoindole–oxadiazole conjugates as potential anti-SARS-CoV-2 agents: in silico and in vitro studies
- (2022) Rana M. El-Masry et al. NEW JOURNAL OF CHEMISTRY
- An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
- (2022) Awadhesh Kumar Singh et al. Diabetes & Metabolic Syndrome-Clinical Research & Reviews
- Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects
- (2022) Hong-jie Qian et al. ACTA PHARMACOLOGICA SINICA
- Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease
- (2022) János András Mótyán et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Are COVID surges becoming more predictable? New Omicron variants offer a hint
- (2022) Ewen Callaway NATURE
- Hundreds of COVID trials could provide a deluge of new drugs
- (2022) Heidi Ledford NATURE
- Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report
- (2022) Marios Prikis et al. TRANSPLANTATION PROCEEDINGS
- A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
- (2022) Nada A Ashour et al. Drug Design Development and Therapy
- Molnupiravir and Its Antiviral Activity Against COVID-19
- (2022) Lili Tian et al. Frontiers in Immunology
- Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands of the Free Fatty Acid Pocket of the SARS‐CoV‐2 Spike Protein
- (2021) Deborah Karen Shoemark et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial
- (2021) Patricia R. M. Rocco et al. EUROPEAN RESPIRATORY JOURNAL
- Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
- (2021) Vicky Mody et al. Communications Biology
- Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2
- (2021) Wendy P. Painter et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Kinetic characterization and inhibitor screening for the proteases leading to identification of drugs against SARS-CoV-2
- (2021) Chih-Jung Kuo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19
- (2021) Steven S. Good et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
- (2021) Masoud Solaymani-Dodaran et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19
- (2021) Eduardo López-Medina et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
- (2021) Angela Wahl et al. NATURE
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
- (2021) NEW ENGLAND JOURNAL OF MEDICINE
- Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
- (2021) Kris M. White et al. SCIENCE
- Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets
- (2021) Rory D. de Vries et al. SCIENCE
- Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
- (2021) Jerzy Osipiuk et al. Nature Communications
- Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2
- (2021) Ewelina Weglarz-Tomczak et al. Scientific Reports
- Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19
- (2021) Kas Steuten et al. ACS Infectious Diseases
- Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
- (2021) Markus Hoffmann et al. EBioMedicine
- Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir
- (2021) Ross Martin et al. ANTIVIRAL RESEARCH
- SARS-CoV-2 Papain-Like Protease Potential Inhibitors—In Silico Quantitative Assessment
- (2021) Adam Stasiulewicz et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- β-D-N 4-hydroxycytidine (NHC) Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
- (2021) Shuntai Zhou et al. JOURNAL OF INFECTIOUS DISEASES
- Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
- (2021) Shuofeng Yuan et al. NATURE
- Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia
- (2021) Luca Braga et al. NATURE
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Shabir A. Madhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen
- (2021) Jordi Rodon et al. Frontiers in Pharmacology
- Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein–Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2
- (2021) Damir Bojadzic et al. ACS Infectious Diseases
- Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance
- (2021) Alfredo Mari et al. Microorganisms
- Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19
- (2021) Gilmar Reis et al. JAMA Network Open
- Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase
- (2021) Souradeep Basu et al. BIOCHEMICAL JOURNAL
- Coupling of N7-methyltransferase and 3′-5′ exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading
- (2021) Liming Yan et al. CELL
- Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
- (2021) Saye H Khoo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
- (2021) Rana Abdelnabi et al. JOURNAL OF INFECTIOUS DISEASES
- Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID‐19 patients
- (2021) Saeed Kalantari et al. JOURNAL OF MEDICAL VIROLOGY
- In silico Studies on the Interaction between Mpro and PLpro From SARS‐CoV‐2 and Ebselen, its Metabolites and Derivatives
- (2021) Pablo Andrei Nogara et al. Molecular Informatics
- Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
- (2021) Evdoxia Kyriazopoulou et al. NATURE MEDICINE
- Potent SARS-CoV-2 mRNA Cap Methyltransferase Inhibitors by Bioisosteric Replacement of Methionine in SAM Cosubstrate
- (2021) Olga Bobiļeva et al. ACS Medicinal Chemistry Letters
- In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2
- (2021) Agnieszka M. Szemiel et al. PLoS Pathogens
- Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection
- (2021) Yu Ling Tan et al. Frontiers in Cellular and Infection Microbiology
- The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors
- (2021) Tomáš Otava et al. ACS Infectious Diseases
- Recent advances in developing small-molecule inhibitors against SARS-CoV-2
- (2021) Rong Xiang et al. Acta Pharmaceutica Sinica B
- Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study
- (2021) Augusto Di Castelnuovo et al. Frontiers in Medicine
- Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
- (2021) John McCoy et al. Frontiers in Medicine
- Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib
- (2021) Eric J Niesor et al. ACS Omega
- Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2
- (2021) Yuanchao Xie et al. CELL RESEARCH
- Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2
- (2021) Sanjay Kumar Dey et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
- (2021) Robert L. Gottlieb et al. NEW ENGLAND JOURNAL OF MEDICINE
- An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
- (2021) Dafydd R. Owen et al. SCIENCE
- Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports
- (2021) Elisabeth Mahase BMJ-British Medical Journal
- The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
- (2021) Rana Abdelnabi et al. EBioMedicine
- Molnupiravir in COVID-19: A systematic review of literature
- (2021) Awadhesh Kumar Singh et al. Diabetes & Metabolic Syndrome-Clinical Research & Reviews
- The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer
- (2020) Sundy N.Y. Yang et al. ANTIVIRAL RESEARCH
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
- (2020) Shuai Xia et al. Cellular & Molecular Immunology
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
- (2020) Roujian Lu et al. LANCET
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- A new coronavirus associated with human respiratory disease in China
- (2020) Fan Wu et al. NATURE
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
- (2020) Guangdi Li et al. NATURE REVIEWS DRUG DISCOVERY
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
- (2020) Qihui Wang et al. CELL
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- (2020) Alexandra C. Walls et al. CELL
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
- (2020) Shuai Xia et al. CELL RESEARCH
- The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients
- (2020) Jing Yuan et al. INFLAMMATION RESEARCH
- Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
- (2020) Fabrizio Cantini et al. JOURNAL OF INFECTION
- Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
- (2020) Lisi Deng et al. JOURNAL OF INFECTION
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
- (2020) Ivan Fan-Ngai Hung et al. LANCET
- Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
- (2020) Denisa Bojkova et al. NATURE
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
- (2020) David E. Gordon et al. NATURE
- Structural basis of receptor recognition by SARS-CoV-2
- (2020) Jian Shang et al. NATURE
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
- (2020) Zhenming Jin et al. NATURE
- The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin
- (2020) Ehud Chorin et al. NATURE MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
- (2020) Joshua Geleris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effective treatment of severe COVID-19 patients with tocilizumab
- (2020) Xiaoling Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structure of the RNA-dependent RNA polymerase from COVID-19 virus
- (2020) Yan Gao et al. SCIENCE
- Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
- (2020) Linlin Zhang et al. SCIENCE
- Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
- (2020) Xiuyuan Ou et al. Nature Communications
- Interferon-α2b Treatment for COVID-19
- (2020) Qiong Zhou et al. Frontiers in Immunology
- Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
- (2020) Cynthia Liu et al. ACS Central Science
- The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
- (2020) Xi Wang et al. Cell Discovery
- Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
- (2020) Qingxian Cai et al. Engineering
- HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19
- (2020) Francesca Romana Spinelli et al. Science Immunology
- Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production
- (2020) Natalia Fintelman-Rodrigues et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
- (2020) Leon Caly et al. ANTIVIRAL RESEARCH
- Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex
- (2020) James Chen et al. CELL
- Current and future therapeutical approaches for COVID-19
- (2020) Yongtao Duan et al. DRUG DISCOVERY TODAY
- Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer
- (2020) Tie Zhou et al. EUROPEAN JOURNAL OF CANCER
- Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)
- (2020) W. Joost Wiersinga et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
- (2020) Abdo A. Elfiky LIFE SCIENCES
- Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
- (2020) Markus Hoffmann et al. NATURE
- Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
- (2020) Laura Riva et al. NATURE
- Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
- (2020) Pauline Maisonnasse et al. NATURE
- Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
- (2020) Donghyuk Shin et al. NATURE
- Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2
- (2020) Yuan-Lin Kang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Type I and III interferons disrupt lung epithelial repair during recovery from viral infection
- (2020) Jack Major et al. SCIENCE
- Distinct conformational states of SARS-CoV-2 spike protein
- (2020) Yongfei Cai et al. SCIENCE
- The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner
- (2020) Mizuki Yamamoto et al. Viruses-Basel
- Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin
- (2020) Petra Krafcikova et al. Nature Communications
- A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, a Pilot Study
- (2020) Zhigang Ren et al. Advanced Science
- Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
- (2020) Jun Chen et al. Open Forum Infectious Diseases
- Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme
- (2020) Arun Bahadur Gurung et al. JOURNAL OF KING SAUD UNIVERSITY SCIENCE
- Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study)
- (2020) Juliana Cepelowicz Rajter et al. CHEST
- Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
- (2020) Theresa Klemm et al. EMBO JOURNAL
- Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
- (2020) Yan Lou et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Characteristics of SARS-CoV-2 and COVID-19
- (2020) Ben Hu et al. NATURE REVIEWS MICROBIOLOGY
- Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects
- (2020) Ya-Wen Cheng et al. Cell Reports
- Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti–COVID-19 drug design
- (2020) Wioletta Rut et al. Science Advances
- Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men
- (2020) Ryan M. Samuel et al. Cell Stem Cell
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2
- (2020) Yuanyuan Qiao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules
- (2020) Kirill Gorshkov et al. ACS Infectious Diseases
- High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance
- (2020) Aditya K. Padhi et al. iScience
- Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
- (2020) Zarir F. Udwadia et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors
- (2019) Robert N. Kirchdoerfer et al. Nature Communications
- Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
- (2019) Maria L. Agostini et al. JOURNAL OF VIROLOGY
- Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
- (2019) Mart Toots et al. Science Translational Medicine
- Coronaviruses — drug discovery and therapeutic options
- (2016) Alimuddin Zumla et al. NATURE REVIEWS DRUG DISCOVERY
- Recent progress in the discovery of inhibitors targeting coronavirus proteases
- (2016) Haofeng Wang et al. VIROLOGICA SINICA
- The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds
- (2015) Yahira M. Báez-Santos et al. ANTIVIRAL RESEARCH
- Suppressive effects of androgens on the immune system
- (2015) Abhishek Trigunaite et al. CELLULAR IMMUNOLOGY
- Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
- (2015) Jasper Fuk-Woo Chan et al. JOURNAL OF INFECTIOUS DISEASES
- Nitazoxanide: A first-in-class broad-spectrum antiviral agent
- (2014) Jean-François Rossignol ANTIVIRAL RESEARCH
- X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases
- (2014) Yahira M. Báez-Santos et al. JOURNAL OF MEDICINAL CHEMISTRY
- Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial
- (2014) Jason Haffizulla et al. LANCET INFECTIOUS DISEASES
- The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis
- (2014) J. M. Lucas et al. Cancer Discovery
- The newly emerged SARS-Like coronavirus HCoV-EMC also has an “Achilles’ heel”: current effective inhibitor targeting a 3C-like protease
- (2013) Zhilin Ren et al. Protein & Cell
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started